By Paul Hoskins and Ben Hirschler DUBLIN/LONDON (Reuters) - Shares in Irish drugmaker Elan Corp PLC ELN lost half their value on Friday while partner Biogen Idec tumbled 25 percent as renewed safety concerns call into question the future of their multiple sclerosis...
LONDON (Reuters UK) - Shares in Irish drugmaker Elan ELN lost a quarter of their value on Wednesday as detailed clinical trial results for its new Alzheimer's drug bapineuzumab proved mixed, disappointing bullish investors. Researchers told the International Conference on Alzheimer's Disease in Chicago that,...
In what is becoming a sadly common ritual, Wyeth and Elan are pressing forward with an expensive, large-scale "phase III" trial of a risky drug based on wishful thinking and shoddy statistical analysis. The drug in question is bapineuzumab, a monoclonal antibody intended to treat Alzheimer's disease...
By Julie Steenhuysen CHICAGO (Reuters)- Keenly awaited details on Elan ELN ELN and Wyeth's WYE new Alzheimer's drug bapineuzumab show it raised the risk of a potentially serious side effect, but may help people who do not have a common genetic risk of...
By Julie Steenhuysen CHICAGO (Reuters UK)- Keenly awaited details on Elan ELN ELN and Wyeth's WYE new Alzheimer's drug bapineuzumab show it raised the risk of a potentially serious side effect, but may help people who do not have a common genetic risk of the...
The failure of Myriad Genetics' experimental Alzheimer's drug Flurizan is surely unfortunate news for those with the disease and their families, but it also reflects badly on the Danish pharma H. Lundbeck, which paid Myriad $100 million on May 22 for European rights to the drug. Since Myriad has discontinued...
New genetic tests for adult-onset diseases raise concerns about possible adverse selection in insurance markets. To test for this behavior, this report reveals about 148 cognitively normal people participating in a randomized clinical trial of genetic testing for Alzheimer's disease for one year after risk assessment and Apolipoprotein E APOE...
The death of former President Ronald Reagan has focused new attention on Alzheimer's research, which is flagging, except for a new imaging clinical trial expected to begin this fall. The National Institute on Aging NIA, which is the NIH's leading funder of Alzheimer's clinical research, has set aside $40 million...
Alzheimer's disease, one of the most frightening memory-robbing disorders, hampers the lives of some 4 to 5 million older Americans. Individuals with Alzheimer's disease may have trouble recalling addresses, major events, or the name of the President. Making meals and managing finances can become difficult. Over time problems with memory...
This white paper report proposes an alternative image feature based statistical learning approach, in addition to anatomical structural morphology analysis, to better classify MR image classes. It basically involves in formulating this as a supervised learning problem, where the MR image labels are given. The key element is to learn...
Although FDA-approved Alzheimer's disease AD treatment strategies cholinesterase inhibitors and memantine offer proven benefits, providers recognize unmet needs beyond what is currently available. This review highlights the urgent need to systematically test additional rational drug combinations and the need for future trials to enroll adequate sample sizes and utilize relevant...
M2 PRESSWIRE-12 February 2004-Visiongain: Visiongain launch leading Neurodegenerative event, as major breakthrough is made in stem cell technologyC1994-2004 M2 COMMUNICATIONS LTD RDATE:02122004 The treatment of Neurodegenerative diseases, such as Alzheimer`s has always been cited as one of the main potential uses...
M2 PRESSWIRE-23 February 2003-Research and Markets: Treatment Algorithms 2002: Alzheimer's Disease - Aricept: the physicians choiceC1994-2003 M2 COMMUNICATIONS LTD RDATE:02202003 Over the last twelve months, the Alzheimer''s disease market has particularly eventful. The most exciting events have been the recent...
M2 PRESSWIRE-20 February 2003-Research and Markets: Mild Cognitive ImpairmentC1994-2003 M2 COMMUNICATIONS LTD RDATE:02202003 10.5 of people over the age of 60 suffer from MCI. Over a half of these willdevelop Alzheimer`s disease within three to four years.Because of this, various trials...
M2 PRESSWIRE-19 February 2003-Research and Markets: Disease State Management; Clinical Behavioral Health GuidelinesC1994-2003 M2 COMMUNICATIONS LTD RDATE:02182003 Disease State Management; Clinical Behavioral Health Guidelines - Valuable tools for health plans and medical groups to reduce variations in care and improve...
M2 PRESSWIRE-18 February 2003-Research and Markets: Drugs of Tomorrow: Alzheimer`s Disease - Ebixa Set to Expand Billion Dollar MarketC1994-2003 M2 COMMUNICATIONS LTD RDATE:02152003 With increasing patient numbers and the limitations of available therapies, the Alzheimer's disease AD market is an attractive...
M2 PRESSWIRE-18 February 2003-Research and Markets: CNS Vaccines: The Risks and Benefits of Innovative TechnologiesC1994-2003 M2 COMMUNICATIONS LTD RDATE:02152003 Products that demonstrate disease modifying properties are greatly needed in Alzheimer`s disease AD and multiple sclerosis MS. This makes neurology vaccines,...
By Keith Wailoo. Studies in Social Medicine. (Chapel Hill and London: University of North Carolina Press, c. 2001. Pp. [xii], 338. Paper, $16.95, ISBN 0-8078-4896-4; cloth, $34.95, ISBN 0-8078-2584-0.) Examining the history of a rare blood disorder in one southern city...
Business & High Tech Editors ARMONK, N.Y.--BUSINESS WIRE--May 17, 2001 Max Planck Society Will Use New IBM POWER4 Technology to Solve Grand Challenges of Science Germany's most prestigious science institution today selected IBM to build an ultra-powerful supercomputer devoted...
M2 PRESSWIRE-4 May 2001-Texas A&M University: New hope for neurodegenerative disease sufferers C1994-2001 M2 COMMUNICATIONS LTD RDATE:25042001 COLLEGE STATION -- Texas A&M University biologists are studying the genetics of learning and memory in humans, which could help understand aging...
